Publication:


abstract

BACKGROUND:

the objective of this study was to evaluate the Mid-term Outcomes of the Laparoscopic Ileal Interposition into the jejunum (JII-SG) or into the duodenum (DII-SG) Associated with Sleeve Gastrectomy for Type 2 Diabetes mellitus (T2DM) Patients with BMI Below 35.

METHODS:

The procedures were performed on 202 Consecutive patients. Mean age was 52.2 ± 7.5. Mean duration of T2DM was 9.8 ± 5.2 years. Insulin therapy was used by 41.1%. Dyslipidemia was observed in 78.2%, hypertension in 67.3%, nephropathy in 49.5%, retinopathy in 31.2%, coronary heart disease in 11.9%, and other cardiovascular events in 12.9%.

RESULTS:

Mean follow-up was 39.1 months (range, 25-61). Early and late mortality was 0.99% and 1.0%, respectively. Early reoperation was performed in 2.5%. Early and late major complications were 8.4% and 3.5%. Early most frequent complications were pneumonia and ileus. Intestinal obstruction was diagnosed in 1.5%. Mean BMI decreased from 29.7 to 23.5 kg/m(2), mean fasting glucose from 202.1 to 112.2 mg/dl, and mean postprandial glucose from 263.3 to 130 mg/dl. Triglycerides diminished from a mean of 273.4 to 110.3 mg/dl and cholesterol from a mean of 204.7 to 160.1 mg/dl. Hypertension was resolved in 87.5%. Mean hemoglobin A(1c) (HbA(1c)) decreased from 8.7 to 6.2% after the JII-SG and to 5.9% following the DII-SG. HbA(1c) below 7% was seen in 89.9% of the patients and below 6.5% in 78.3%. Overall, 86.4% of patients were off antidiabetic medications.

CONCLUSION:

Both JII-SG and DII-SG demonstrated to be safe, effective, and long-lasting alternatives for the Treatment of T2DM patients with BMI <35. Beyond glycemic control, other benefits were achieved.

Related Articles
Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2).
Surg Obes Relat Dis. 2010
Prospective randomized controlled trial comparing 2 versions of laparoscopic ileal interposition associated with sleeve gastrectomy for patients with type 2 diabetes with BMI 21-34 kg/m(2).
De Paula AL, Stival AR, Macedo A, Ribamar J, Mancini M, Halpern A, Vencio S. Surg Obes Relat Dis. 2010 May-Jun; 6(3):296-304. Epub 2009 Nov 10.
Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29.
Surg Endosc. 2009
Laparoscopic ileal interposition associated to a diverted sleeve gastrectomy is an effective operation for the treatment of type 2 diabetes mellitus patients with BMI 21-29.
DePaula AL, Macedo AL, Mota BR, Schraibman V. Surg Endosc. 2009 Jun; 23(6):1313-20. Epub 2008 Oct 2.
Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients.
J Gastrointest Surg. 2010
Impact on dyslipidemia of the laparoscopic ileal interposition associated to sleeve gastrectomy in type 2 diabetic patients.
DePaula AL, Stival AR, DePaula CC, Halpern A, Vêncio S. J Gastrointest Surg. 2010 Aug; 14(8):1319-25. Epub 2010 Jun 16.
Review Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Pharmacoeconomics. 2004
Review Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP. Pharmacoeconomics. 2004; 22(6):389-411.
Review The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Health Technol Assess. 2009
Review The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. Health Technol Assess. 2009 Sep; 13(41):1-190, 215-357, iii-iv.